News|Articles|July 21, 2015

Jyoti D. Patel on the Progress of Immunotherapy in NSCLC

Key Takeaways

Immunotherapy is showing promise as a treatment for non-small cell lung cancer (NSCLC), with significant advancements reported at the 2015 ASCO meeting.
Jyoti D. Patel highlighted the progress in immunotherapy for NSCLC, emphasizing its potential to improve patient outcomes.
The 2015 ASCO meeting, attended by nearly 30,000 oncology professionals, showcased pivotal developments in the therapeutic landscape for NSCLC.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer (NSCLC). Patel is reporting on data presented at the 2015 annual meeting of the American Society of Clinical Oncology, a gathering of nearly 30,000 oncology professionals in Chicago.